Journal of Molecular Pharmaceutics & Organic Process Research

Implant Dentistry and Nanotechnology

Department of Periodontology, School of Dentistry and Dental Research Institute, BK21 Program, Seoul National University, France

Dental implants' long-term clinical performance is correlated with their early Osseo integration. The interactions of biological fuids, cells, tissues, and implant surfaces are examined in this sudy through a variety of procedures. Immediately following insertion, implants come into touch with blood proteins and platelets. Mesenchymal sem cell growth will then be necessary for the peri-implant tissue to recover. The chemisry and roughness of the surface play a crucial role in these biological interactions. Physical and chemical characterisics in the nanoscale range may eventually control protein adsorption, cell adhesion, and diferentiation. Nanotechnologies are increasingly being used to alter the surfaces of dental implants.

Ke d : Physicochemical; Nanotechnologies; Peri-implant tissue; Direct bone-to-implant

I d c i

Hoornaert Louarn, Department of Periodontology, School of Dentistry and Dental Research Institute, BK21 Program, Seoul National University, France, E-mail: hoornaert.louarn@gmail.com

01-May-2023, Manuscript No: jmpopr-23-99668, 04-May-2023, pre QC No: jmpopr-23-99668 (PQ), 18-May-2023, QC No: jmpopr-23-99668, 22-May-2023, Manuscript No: jmpopr-23-99668 (R), 29-May-2023, DOI: 10.4172/2329-9053.1000167

Louarn H (2023) Implant Dentistry and Nanotechnology. J Mol Pharm Org Process Res 11: 167.

constitutional symptoms [7-11].

Conclusion

The main health concerns in developing and poor nations are infectious diseases. Nearly one-third of the homeless population, particularly in developing nations, lacks sufficient access to essential medications. Developing countries are severely impacted by tuberculosis.

Drug-resistant TB poses a significant obstacle to the successful control of the disease in this situation. The goal is to address this by developing or manufacturing better, more potent medications with shorter treatment times, lower toxicity levels, and increased bioavailability. Apart from a few medications, such as quinolones and rifamycins, no significant advancements in ATD therapy have been made to far, and a viable TB vaccine has also remained elusive. The objective is to find a way to stop the spread of the causal organism, however this is challenging, complex, and tough because of the challenges of identification, drug resistance, and patient noncompliance with therapy.

Conflict of Interest